Mail

UK markets closed

FTSE 100
8,139.83
+60.97(+0.75%)
FTSE 250
19,824.16
+222.18(+1.13%)
AIM
755.28
+2.16(+0.29%)
GBP/EUR
1.1679
+0.0022(+0.19%)
GBP/USD
1.2494
-0.0017(-0.13%)
Bitcoin GBP
50,330.48
+367.89(+0.74%)

'We sold £1.5m of product in our first week'

Lyma founder on rise of her wellness company

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

3.0300

+0.0100

(+0.33%)

At close: 04:00PM EDT

3.1624

+0.13

(+4.37%)

After hours:

06:01PM EDT

Currency in USD

Valuation measures⁴

Market cap (intra-day)	97.75M
Enterprise value	94.80M
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	N/A
Price/book (mrq)	2.67
Enterprise value/revenue	N/A
Enterprise value/EBITDA	-2.45

Trading information

Stock price history

Beta (5Y monthly)	0.94
52-week change ³	91.77%
S&P500 52-week change ³	22.36%
52-week high ³	4.4500
52-week low ³	1.3300
50-day moving average ³	3.6190
200-day moving average ³	2.7803

Share statistics

Avg vol (3-month) ³	1.07M
Avg vol (10-day) ³	908.87k
Shares outstanding ⁵	32.26M
Implied shares outstanding ⁶	32.69M
Float ⁸	23.32M
% held by insiders ¹	3.56%
% held by institutions ¹	26.40%
Shares short (15 Apr 2024) ⁴	2.19M
Short ratio (15 Apr 2024) ⁴	1.96
Short % of float (15 Apr 2024) ⁴	6.81%
Short % of shares outstanding (15 Apr 2024) ⁴	6.80%
Shares short (prior month 15 Mar 2024) ⁴	1.88M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	17 Jul 2018
Ex-dividend date ⁴	N/A
Last split factor ²	1:10
Last split date ³	22 Jul 2022

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	0.00%

Management effectiveness

Return on assets (ttm)	-144.66%
Return on equity (ttm)	-536.81%

Income statement

Revenue (ttm)	N/A
Revenue per share (ttm)	N/A
Quarterly revenue growth (yoy)	N/A
Gross profit (ttm)	N/A
EBITDA	-38.77M
Net income avi to common (ttm)	-37.98M
Diluted EPS (ttm)	-3.1100
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	9.56M
Total cash per share (mrq)	0.3
Total debt (mrq)	552.98k
Total debt/equity (mrq)	N/A
Current ratio (mrq)	0.81
Book value per share (mrq)	-0.36

Cash flow statement

Operating cash flow (ttm)	-32.38M
Levered free cash flow (ttm)	-15.44M